Core Viewpoint - Samsung Medical (601567) has shown a positive stock performance with a closing price of 24.21 CNY, reflecting a 2.54% increase from the previous week, indicating investor confidence and market interest in the company [1] Company Announcements Summary - Samsung Medical's subsidiary, Foxytech Sp.zo.o, has signed a contract for a smart meter project in Poland worth approximately 185 million CNY, equivalent to 9.39 million Polish Zloty [1] - The project involves supplying single-phase and three-phase smart meters to TAURON Dystrybucja S.A., a company focused on the development and operation of the power grid in southern Poland [1] - The contract is expected to positively impact Samsung Medical's operational performance, contributing 1.26% to the audited revenue for the fiscal year 2024 [1] - This contract marks a significant breakthrough for Samsung Medical in the European smart meter market, enhancing its overseas business layout and competitive advantage [1]

Group 1 - Samsung Medical's subsidiary Foxytech signed a contract for a smart meter project in Poland worth approximately 93.9 million Polish Zloty, equivalent to about 185 million RMB, representing 1.26% of the company's audited revenue for 2024 [1] - The project is with TAURON Dystrybucja S.A., a developer and operator of the southern Polish power grid, and involves the provision of single-phase and three-phase smart meters [1] - The company has secured a total of 1.133 billion RMB in overseas orders since 2025, including significant contracts in Indonesia, the USA, Hungary, and Brazil [1] Group 2 - Samsung Medical's main business segments are smart power distribution and medical services, with the former contributing the majority of revenue [2] - The company has established production bases and sales centers in five countries and has sales centers in six additional countries, covering over 70 regions [2] - In 2024, overseas revenue reached 2.714 billion RMB, a year-on-year increase of 38.4%, with overseas production capacity accounting for 50% of its overseas business [2] Group 3 - The company is optimistic about overseas market demand in 2025, driven by the need for renewable energy integration, increased electricity load, and aging grid renovations [3] - Global grid investment is expected to exceed 400 billion USD in 2025, supported by policies promoting the application of smart power distribution products [3] - In the domestic market, the company has secured approximately 660 million RMB in contracts from major state-owned power grid companies in the last three months [3]

Group 1 - The company’s subsidiary, Nansen Instrumentos de Precision de Mexico, won a contract for the Nexgrid smart meter framework project in the USA, with a total contract value of $29.55 million, approximately 212 million RMB [2][5][7] - The contract involves the supply of single-phase, two-phase, and three-phase smart meters, marking a significant breakthrough for the company in the North American smart meter market [3][7] - The contract amount represents about 1.45% of the company's audited revenue for the fiscal year 2024, indicating a positive impact on the company's operational performance [3][5] Group 2 - The company plans to repurchase and cancel 5,755,371 shares, reducing its total share capital from 1,411,006,571 shares to 1,405,251,200 shares [9][14] - The share repurchase was approved in meetings held on May 28 and June 13, 2025, reflecting the company's confidence in its future development and long-term value [10][12] - The cancellation of shares is expected to enhance shareholder returns and investor confidence without significantly affecting the company's financial status or operational capabilities [15][16]

Core Viewpoint - Samsung Medical has successfully secured a contract for smart meter products in the North American market, marking a significant breakthrough in its overseas expansion efforts [1] Group 1: Contract Details - The contract was awarded to Samsung Medical's subsidiary, Nansen Instrumentos de Precision de Mexico, for the Nexgrid smart meter framework project [1] - The total contract amount is $29.555 million, equivalent to approximately 212 million RMB [1] Group 2: Strategic Implications - This contract represents a key achievement in Samsung Medical's strategy to actively explore and expand its presence in overseas markets [1] - The successful bid enhances the company's competitive advantage in the overseas smart meter market [1]